KRIBIOLISA™ Sunitinib (SUTENT™) ELISA

Introduction:

Sunitinib (SUTENT) is a medication used to treat cancer. It is a small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor that was approved by the FDA for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). Sunitinib Malate is an antineoplastic agent, Flk-1 inhibitor, and ATP-competitive inhibitor of PDGFRβ.

Intended Use:

This kit is used for quantitative estimation of Sunitinib in serum, plasma and cell culture supernatant using a competitive inhibition principle.

Principle:

The KRIBIOLISA™ Sunitinib ELISA is a competitive inhibition immunoassay for the determination of Sunitinib. The microplate is coated with VEGFA protein. VEGFA protein is a known dimeric glycoprotein which functions as a ligand for the receptor VEGFR2 (Flk1). Samples and standards containing Sunitinib is added to the plate with HRP conjugated VEGFR-2 from the kit simultaneously. The Sunitinib in the samples and standard will inhibit the binding of VEGFR-2 to the microplate. The amount of Sunitinib is inversely proportional to the color developed in the microplate post addition of TMB substrate and stopping the reaction. The absorbance is read at 450 nm.